問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Dermatology

Division of Others-Pediatric Dermatology, Cosmeceuticals, Laser and Rejuvenation Treatment, Atopic dermatitis

Division of Pediatrics

Taipei Chang Gung Medical Foundation

Division of Dermatology

更新時間：2023-09-19

楊靜宜Yang, Chin-Yi
  • Principal Investigator
  • Clinical Trial Experience (year) 18 years

  • sophiachinyi@cgmh.org.tw

Recruiting Trial

26Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

楊靜宜

Linkou Chang Gung Medical Foundation

Division of Dermatology

List

31Cases

2018-08-01 - 2023-07-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2014-04-01 - 2017-09-30

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2021-10-01 - 2024-03-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2021-09-01 - 2023-07-31

Phase II

Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects with Prurigo Nodularis

  • Condition/Disease

    Prurigo Nodularis/Pruritis

  • Test Drug

    KPL-716/ vixarelimab

Participate Sites
4Sites

Recruiting4Sites

2019-07-10 - 2020-02-12

Phase II

A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Assess the Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

  • Condition/Disease

    Atopic Dermatitis

  • Test Drug

    REGN3500 and REGN668 (Dupilumab)

Participate Sites
4Sites

Terminated4Sites

2018-11-01 - 2019-12-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate to Severe Atopic Dermatitis BREEZE-AD7

  • Condition/Disease

    Moderate to Severe Atopic Dermatitis

  • Test Drug

    Baricitinib (LY3009104)

Participate Sites
5Sites

Terminated5Sites

李婉若
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2019-04-01 - 2022-06-20

Phase III

A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.

  • Condition/Disease

    Atopic Dermatitis

  • Test Drug

    Lebrikizumab

Participate Sites
7Sites

Recruiting7Sites

2015-08-14 - 2017-12-31

Phase II

A multicenter, randomized, double-blind, placebo and active controlled Phase 2b dose-finding study of QGE031 as add-on therapy to investigate the efficacy and safety in patients with Chronic Spontaneous Urticaria (CSU)

  • Condition/Disease

    Chronic Spontaneous Urticaria (CSU)

  • Test Drug

    QGE031

Participate Sites
3Sites

Terminated3Sites

2016-06-01 - 2019-08-31

Phase II

An open label, multicenter, extension study to evaluate the long-term safety of QGE031 240 mg s.c. given every 4 weeks for 52 weeks in Chronic Spontaneous Urticaria patients who completed study CQGE031C2201

  • Condition/Disease

    Chronic Spontaneous Urticaria

  • Test Drug

    QGE031

Participate Sites
3Sites

Terminated3Sites

鐘文宏
Linkou Chang Gung Medical Foundation

Division of Dermatology

2018-09-01 - 2022-08-03

Phase III

A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines

  • Condition/Disease

    Chronic Spontaneous Urticaria (CSU)

  • Test Drug

    QGE031/ligelizumab

Participate Sites
3Sites

Recruiting3Sites

黃毓惠
Linkou Chang Gung Medical Foundation

Division of Dermatology

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB